Experimental CAR-T therapy for rare solid tumors stalls after single patient
NCT ID NCT07123493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a personalized cell therapy called anti-ALPP CAR-T cells in people with advanced solid tumors that have the ALPP protein. Only one participant was enrolled before the study was terminated. The main goal was to check safety and find the right dose, not to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-ALPP CAR-T cells
What this could lead to
If successful, this approach could point toward a new treatment option for certain hard-to-treat solid tumors that express ALPP.
What could go wrong
This was a very early, small trial (only 1 participant) that was terminated, so results are extremely limited. CAR-T cell therapy can cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC SOLID TUMORS WITH POSITIVE ALPP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China